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Abstract. The efficacy of percutaneous transluminal angio-
plasty (PTA) is usually expressed as the angiographic result.
Access flow (Qa) measurements offer a means to quantify the
functional effects. This study was performed to evaluate the
short-term functional and angiographic effects of PTA and to
determine the longevity of the functional effects during the
follow-up period. Patients with an arteriovenous graft (AVG)
or an arteriovenous fistula (AVF) who were eligible for PTA
(Qa values of 600 ml/min) were included. Ultrasound-dilu-
tion Qa measurements were obtained shortly before PTA and
periodically after PTA, beginning 1 wk after the procedure.
The short-term effects were expressed as the increase in Qa and
the reduction of stenosis. The long-term effects were expressed
as patency and the decrease in Qa after PTA. Ninety-eight PTA
procedures for 60 patients (65 AVG and 33 AVF) were ana-
lyzed. Qa improved from 371  17 to 674  30 ml/min for
AVG and from 304  24 to 638  51 ml/min for AVF (both
P  0.0001). In 66% (AVG) and 50% (AVF) of cases, Qa
increased to levels of 600 ml/min. The degree of stenosis
decreased from 65  3 to 17  2% for AVG and from 72 
5 to 23  7% for AVF (both P  0.005). The reduction of
stenosis was not correlated with Qa (r2  0.066). Six-month
unassisted patency rates after PTA were 25% for AVG and
50% for AVF. The decreases in Qa were 3.7  0.8 ml/min per
d for AVG and 1.8  0.9 ml/min per d for AVF. Qa values
before PTA and Qa were correlated with the subsequent
decrease in Qa (P  0.005). In conclusion, Qa increases after
PTA but, in a substantial percentage of cases, not to levels of
600 ml/min. Qa values before PTA and the increase in Qa
were correlated with long-term outcomes, whereas angio-
graphic results were not. These data, combined with literature
data, suggest that there is optimal timing for PTA.
Vascular access complications account for considerable mor-
bidity and deaths among hemodialysis patients. In the United
States, these complications are responsible for up to 25% of all
hospitalizations among dialysis patients (1–3). The European
Dialysis and Transplant Association does not collect data on
this issue, but it is likely that data for Europe and elsewhere
would be comparable.
Thrombosis is the leading cause of vascular access compli-
cations. Thrombosis is almost always associated with the pres-
ence of stenosis. Percutaneous transluminal angioplasty (PTA)
is an accepted treatment for stenotic lesions (3). Routine sur-
veillance programs for the early detection of stenoses, followed
by angioplasty, have been demonstrated to substantially reduce
the number of thromboses per patient-year (4–7). However,
repeated PTA treatment is often necessary, because restenosis
occurs frequently. Although the short-term success rates for
PTA range from 85 to 98% (8), patency rates at 6-mo fol-
low-up assessments vary from 38 to 63% (4,9–11).
Several studies have demonstrated that the angiographic
extent of stenotic lesions before and after PTA is poorly
correlated with subsequent patency (9,11–14). Recently, the
Society of Cardiovascular and Interventional Radiology
(SCVIR) Technology Assessment Committee recommended
that PTA efficacy should be expressed by both angiographic
and functional parameters (15). In particular, access flow
(Qa) measurements offer the opportunity to quantify and
monitor the functional effects of PTA.
The purpose of this study was to assess access function
among patients undergoing PTA. We quantified the short-term
functional and angiographic effects of PTA. In addition, we
determined the longevity of the functional effects during the
follow-up period. Finally, we addressed the question of
whether functional variables are predictive of long-term
outcomes.
Materials and Methods
Patients
This prospective, observational, intervention study was performed
in nine Dutch hemodialysis centers, in which a well defined surveil-
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lance protocol was instituted as part of routine patient care. All
chronic hemodialysis patients with permanent arteriovenous grafts
(AVG) or arteriovenous fistulae (AVF) who were referred for angiog-
raphy because predetermined Qa threshold levels had been reached
were eligible to enter the study. The surveillance protocol included
periodic Qa measurements and angiography with PTA for patients
thus selected.
Qa Surveillance Protocol
Qa was measured at least every 8 wk, using the ultrasound-
hemodilution technique (Transonic Systems Inc., Ithaca, NY). Bench
and clinical validations are presented elsewhere (16,17).
The surveillance protocol was discussed in detail previously (7). In
brief, Qa determinations consisted of the average of three single
measurements made within the first 30 min of the dialysis session, at
a fixed pump flow rate (200 ml/min). If Qa levels reached values
between 600 and 800 ml/min, then measurements were repeated at
least every 4 wk. Patients were referred for angiography whenever Qa
values were 600 ml/min. Patients referred for angiography on the
basis of other criteria, e.g., frequent miscannulation, swelling of the
arm, or high venous pressure, were excluded. Patients with a history
of allergy to iodinated contrast agents were also not included in the
study.
Angiography and PTA
Angiography and PTA procedures were performed as soon as
possible (usually 7 d) after detection of the low Qa level (600
ml/min). Digital subtraction angiography was performed for observa-
tion of the complete vascular access and location of the stenosis. Any
luminal reduction of 50% was treated with PTA during the same
session. The same PTA technique was used for all patients. First, the
stenotic lesion was crossed with a guide wire (Boston Scientific Corp.,
Watertown, MA). Then a sheath (Cordis Europe, Roden, The Neth-
erlands) was introduced. The PTA balloon catheter was passed over
the guide wire to the location of the stenosis. In general, the high-
pressure balloons had a diameter of 6 mm, although larger balloons
(up to 10 mm) could be used for large proximal veins (several brands
of catheters were used). At the stenotic site, the balloon was inflated
to at least 10 atmospheres of pressure and maintained for approxi-
mately 2 min. In resistant cases, pressures of up to 20 atmospheres
were used and maintained for 10 min. No heparin, vasodilators, or
local anesthetics were administered during the procedure. Immedi-
ately after PTA, angiograms were obtained for evaluation of the
results of the procedure. The interventional radiologist considered
PTA procedures successful when the residual diameter of the stenosis
was 25%. After PTA, Qa measurements were performed within 1
wk and then at least at 4-wk intervals. If Qa decreased below 600
ml/min, then patients were referred for angiography and repeat PTA
was performed if necessary.
Outcome Variables and Statistical Analyses
The short-term functional effect of PTA on Qa was evaluated by
calculation of Qa, i.e., the difference between Qa before (Qapre) and
just after (Qapost) PTA. The long-term functional effect was assessed
as the time to the next intervention, if applicable. When there were
three or more Qa measurements after the PTA, the decrease in Qa was
determined (in milliliters per minute per day). Resistance was calcu-
lated as the mean arterial BP/Qa ratio.
Angiographic data were analyzed by an independent radiologist.
Only cases for which adequate biplanar angiograms of the stenotic
areas had been obtained both before and after PTA were included. The
degree of stenosis was assessed before PTA (baseline) and after PTA
(post-PTA) as the ratio of the maximal lumen reduction to an adjacent
normal graft/vessel diameter (expressed as a percentage; 0%  no
stenosis, 100%  occlusion). Stenosis reduction attributable to PTA
was calculated as the difference between baseline stenosis and post-
PTA stenosis.
Data are presented as mean  SEM, unless indicated otherwise.
Differences in Qa and Qa values for different time points and
subgroups of patients were calculated with two-tailed t tests. Pearson
analysis was used for correlation purposes. Post-PTA primary pa-
tency, i.e., the period of time that elapsed after intervention until
access thrombosis or reintervention (surgical and/or radiologic), was
calculated using a life-table analysis. To compare post-PTA survival
rates for AVF and AVG, a (two-sided) log-rank test was used. P
values of 0.05 were considered significant.
Results
Patients
Sixty patients who were referred for angiography were in-
cluded. A total of 98 PTA procedures were performed. For 35
patients with AVG, 65 PTA procedures were performed. For
the remaining 25 patients with AVF, 33 PTA procedures were
performed. Patient and graft characteristics are presented in
Table 1.
Table 1. Patient and access characteristicsa
AVG AVF Total
No. of patients 35 25 60
Mean age (range) (yr) 62.7 (37.2 to 82.6) 66.8 (34.6 to 83.7) 64.4 (34.6 to 83.7)
Gender
male 6 16 22
female 29 9 38
Diabetes mellitus 9 (26%) 4 (16%) 13 (22%)
Coumarin therapy 19 (54%) 10 (40%) 29 (48%)
Mean age of access (range) (d) 629 (2 to 1893) 1088 (30 to 2926) 806 (2 to 2926)
Lower arm/upper arm 31/4 21/4 52/8
a AVG, arteriovenous grafts; AVF, arteriovenous fistulae.
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Functional Results
Short-Term Results. In all cases, the first Qa measure-
ment was performed within 7 d after PTA, usually during the
first dialysis session after PTA. For AVG, Qa improved from
371  17 to 674  30 ml/min (P  0.0001). Mean arterial BP
remained stable after PTA (97  2 versus 96  2 mmHg),
indicating that the increase in Qa represented a decrease in
resistance. Qapost values of 600 ml/min were reached in 62%
of cases (40 of 65 cases) (Figure 1A). A negative correlation
was observed between Qapre and Qa (P  0.0019, r 
0.38). Qapre values did not differ for diabetic patients versus
nondiabetic patients (340  32 versus 386  19 ml/min, P 
0.20). PTA tended to be less effective for diabetic patients than
for nondiabetic patients (Qa, 228 50 and 337 41 ml/min,
respectively; P  0.06). The ages of the AVG and of the
patients were not correlated with Qa. Multiple procedures
were performed for 15 patients (Table 2). For patients who
were treated twice, Qa values were 355  68 and 424  79
ml/min after the first and second PTA procedures, respectively
(n  15, P  NS). For patients who were treated three times,
Qa values were 315  98, 484  112, and 345  51 ml/min
after the first, second, and third PTA procedures, respectively
(n  10, P  NS). For 15 patients, the PTA procedure was the
first intervention for the AVG. Qa values for those patients
did not differ from the values for patients who underwent a
second or later PTA (287  61 versus 313  41 ml/min, P 
0.72). Unassisted patency rates also did not differ.
For AVF, Qa improved from 304  24 to 638  51 ml/min
(P  0.0001) (Figure 1B); 52% of PTA procedures (17 of 33
cases) resulted in Qapost levels of 600 ml/min. The Qa was
not related to Qapre for AVF (r  0.06). Diabetes mellitus or
the ages of the AVF or patients did not significantly affect the
results for AVF. Only four patients underwent two PTA pro-
cedures (Table 2), and those patients demonstrated Qa values
of 541  173 and 285  144 ml/min after the first and second
PTA procedures, respectively (P  0.09).
Long-Term Results. For 35% of all patients (21 of 60
patients), multiple procedures were performed. Repeat PTA
procedures were more common for AVG than for AVF [43%
(15 of 35 cases) versus 24% (six of 25 cases)] (Table 2). The
mean time interval to repeat PTA was shorter for AVG than for
AVF (109  12 versus 169  32 d, P  0.04). In cases
involving two PTA procedures, the time interval between the
first and second PTA procedures was 113  18 d (n  15). In
cases involving three PTA procedures, the time intervals be-
tween the first and second and the second and third PTA
procedures were 122  26 and 101  21 d, respectively (n 
10, P  NS).
Decreases in Qa values after PTA were 3.7 0.8 ml/min per
d for AVG (n  38) and 1.8  0.9 ml/min per d for AVF (n
 24, P  0.06). Coumarin use and diabetes mellitus did not
affect the decrease in Qa after PTA. However, there was a
correlation between Qapre levels and the subsequent decrease
in Qa after PTA (r  0.43, P  0.005). Also, Qa was
correlated with the decrease in Qa after PTA (r  0.48, P 
0.0009).
The median primary patency time after PTA for AVG was
97 d. The post-PTA primary patency rates for AVG at 1, 3, and
6 mo were 100, 56, and 25%, respectively. The median patency
time for AVF was 161 d. Post-PTA primary patency rates for
Figure 1. Access flow (Qa) results within 1 wk after percutaneous
transluminal angioplasty (PTA) for arteriovenous grafts (A) and ar-
teriovenous fistulae (B) (both P  0.0001).
Table 2. Number of patients who underwent single and
multiple PTA proceduresa
AVG AVF Total
Single PTA procedure 20 (20) 19 (19) 39 (39)
Multiple PTA procedures 15 (45) 6 (14) 21 (59)
two 5 (10) 4 (8) 9 (18)
three 6 (18) 2 (6) 8 (24)
four 3 (12) 0 3 (12)
five 1 (5) 0 1 (5)
Total 35 (65) 25 (33) 60 (98)
a PTA, percutaneous transluminal angioplasty. Values in
parentheses represent the number of PTA procedures.
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AVF at 1, 3, and 6 mo were 100, 92, and 50%, respectively.
Log-rank comparison analysis of intervention-free survival
curves demonstrated a significant difference in favor of the
AVF (P  0.031).
During the available follow-up period, no unpredicted
thrombotic events (i.e., accesses thrombosed with a Qa of
600 ml/min) occurred. For six AVG with Qa that remained
below 600 ml/min after PTA, thrombosis occurred within
weeks after PTA. Those cases are considered predicted throm-
boses. Furthermore, some thromboses occurred among patients
with low Qa during the wait for PTA. Those accesses were not
included in this analysis, because no PTA procedure was
performed.
Angiographic Results
For AVG, 48 PTA procedures (74%) were performed on
single lesions [38 venous stenoses (58%), nine midgraft steno-
ses (14%), and one arterial stenosis (2%)]. Seventeen PTA
procedures (26%) were performed on two stenotic lesions [12
cases (18%) of venous and midgraft stenoses and five cases
(8%) of arterial and venous stenoses]. Log-rank survival anal-
ysis demonstrated no difference in patency rates between AVG
with a single lesion and those with multiple lesions (P 0.74).
Seven PTA procedures (21%) for AVF were for true anasto-
motic lesions, 20 (61%) were for venous lesions (in most cases
located within a few centimeters from the anastomosis), and
six (18%) for combined (venous and anastomotic) lesions. For
92% of all PTA procedures, angiographic improvement of the
stenosis was achieved using a 6-mm balloon. Larger balloons
were occasionally needed for proper dilation of stenoses in
proximal AVF veins. In all cases, PTA was reported to be
successful, i.e., residual luminal reduction of 25%.
For AVG, baseline stenosis was 65  3% and post-PTA
stenosis was 17  2% (n  33, P  0.0001). No correlation
was observed between baseline stenosis and post-PTA stenosis
(r  0.14, P  0.47) or Qapost (r  0.05, P  0.76).
Baseline stenosis was correlated with Qapre (r  0.48, P 
0.008). No correlation was observed between angiographic
(stenosis reduction) and functional (Qa) improvement (r2 
0.066) or between baseline stenosis and the subsequent de-
crease in Qa (r  0.02, P  0.93). Additionally, neither
stenosis reduction (P  0.29) nor post-PTA stenosis (P 
0.07) was correlated with the decrease in Qa after PTA. Log-
rank survival analysis of the lower and upper 50th percentile
baseline stenosis values revealed no difference in survival rates
(P  0.90).
When the AVG group was divided into a group with Qapost
values of 600 ml/min (n  24) and a group with Qapost
values of 600 ml/min (n  41), we observed that there was
no difference in angiographic results between the two groups.
The group with Qapost values of 600 ml/min demonstrated
stenosis of 66  4% before and 19  4% after PTA, whereas
the group with Qapost values of 600 ml/min demonstrated
stenosis of 63  4% before and 14  3% after PTA (P  NS).
The group with Qapost values of600 ml/min exhibited a Qapre
value of 336  24 ml/min and a Qapost value of 441  22
ml/min (Qa  105  24 ml/min). The group with Qapost
values of 600 ml/min exhibited a Qapre value of 392  22
ml/min and a Qapost value of 811  29 ml/min (Qa  419 
40 ml/min). Of the 24 patients with Qapost values of 600
ml/min, six experienced thrombosis within 4 wk after PTA,
eight underwent surgical correction without repeat angiogra-
phy, and repeat angiography demonstrated 61% stenosis for 10.
Two of those patients were subsequently referred for surgical
revision, and eight underwent another PTA procedure. For
AVF, baseline stenosis was 72  5% and post-PTA stenosis
was 23  7% (n  8, P  0.0039).
Discussion
To our knowledge, this is the first study reporting both
angiographic and functional results of PTA for the treatment of
AVG and AVF. This study contains novel information. We
demonstrate that angiographic results are not correlated with
functional results. Importantly, we demonstrate that functional
variables are predictive of long-term outcomes, whereas an-
giographic results are not. The study confirms recent data
indicating that PTA results in a direct increase in Qa of
approximately 250 ml/min (18). We also confirm that a sub-
stantial percentage of PTA procedures are not successful. Fi-
nally, the time to repeat PTA in this study was substantially
shorter than that in other studies (9,18,19), which suggests a
more rapid recurrence of stenosis in this study. The combined
data from these studies suggest that there is an optimal time for
PTA.
On the basis of the vast experience reported in the literature,
the National Kidney Foundation/Kidney Disease Outcomes
Quality Initiative Task Force has suggested PTA as a preferred
treatment for vascular access stenosis (3). In most studies,
post-PTA stenosis is used to express the efficiency of PTA
procedures. However, post-PTA stenosis poorly predicts pa-
tency rates after PTA (9,11–14). Recently, the SCVIR Tech-
nology Assessment Committee recommended reporting both
angiographic and functional data as efficacy parameters for
PTA (15).
Our patients all exhibited Qa values of 600 ml/min, which
is a strong predictor for imminent thrombosis, especially in
grafts (3,20–23). They all exhibited baseline stenosis of
50%, which was treated by PTA. We confirm earlier data
indicating that, on average, Qa increases by approximately 250
to 300 ml/min (18,24). Among the patients with adequate
angiograms, post-PTA stenosis in AVG was 25% in almost
all cases. This is considered to be an adequate angiographic
result (3). However, the decrease in resistance was not corre-
lated with stenosis reduction, indicating that angiographic im-
provement does not necessarily represent functional improve-
ment. Preliminary data for a small group of patients also
indicated that stenosis reduction was not correlated with the
increase in Qa (14). Results for diabetic patients did not differ
from those for nondiabetic patients. The percentage of PTA
procedures that resulted in Qapost values above the threshold
value of 600 ml/min was 66% for AVG and 50% for AVF.
Schwab et al. (18) defined failure of PTA as an increase in Qa
of20%, which occurred for 21% of grafts. This lack of effect
may be caused by rapid recoil of the stenotic lesion, occurring
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in the period between PTA and the first Qa measurement.
Intravascular ultrasonography after PTA demonstrated that im-
mediate elastic recoil occurred in 50% of the stenotic lesions
(25). These findings may also indicate that other stenotic
lesions, which importantly contribute to overall resistance,
were not identified and not treated. Qa measurements during or
immediately after PTA, in the intervention room, could be
helpful for optimization of procedure results (24).
For patients who required multiple procedures, similar in-
creases in Qa were obtained with subsequent PTA procedures.
This finding supports earlier data indicating that patency rates
do not decrease after repeat PTA (9). Lumsden et al. (12)
randomized patients with 50% stenosis to either undergo
PTA or not, and they observed that outcomes did not differ.
Later, the same authors reanalyzed their data and reported that
patency rates did improve but only for grafts without prior
angioplasty or thrombosis (13). In this study, the PTA proce-
dure included was the first intervention for only a minority of
AVG. We were unable to confirm the earlier results indicating
that the outcomes of first interventions are better than those of
second or later interventions.
Long-term results of PTA are usually quantified as primary
patency rates. For AVG, these rates vary from 38 to 64% at 6
mo and from 10 to 40% at 12 mo (8). We observed an
intervention-free primary patency rate at 6 mo of 25% for
AVG. The median time to the next PTA procedure was 97 d,
compared with 5.8 mo in the study by Schwab et al. (18). Their
results seem substantially better than the results presented here,
whereas the short-term functional effects in the two studies are
comparable. Some of the differences between these studies
may be important in this respect. In our study, AVG were
almost exclusively localized in the lower arm, whereas the
study by Schwab et al. (18) included mainly upper-arm AVG.
We selected patients when the threshold of 600 ml/min was
reached, whereas in the other study most patients were referred
when Qa values demonstrated a decrease of20%. As a result,
Qa values before and after PTA differed considerably, i.e., 371
 17 and 674  30 ml/min in this study and approximately
750 and 950 ml/min in the previous study, respectively (18).
The decrease in Qa after PTA was correlated with Qapre,
suggesting that the severity of stenosis before PTA is predic-
tive of the rate of stenosis recurrence. The decrease in Qa was
4.1  1.0 ml/min per d for patients with Qapre values between
100 and 350 ml/min, compared with 2.7 1.2 ml/min per d for
patients with Qapre values between 350 and 600 ml/min. Ad-
ditional support for this notion is derived from data for patients
who underwent PTA because of high venous pressure, who
were not included in this study. For patients (n  12) who
exhibited Qapre levels of 600 to 800 ml/min, the decrease in Qa
was 1.6 1.8 ml/min per d, which perfectly corresponds to the
5.8 mo between consecutive interventions reported by Schwab
et al. (18). Whereas baseline stenosis was correlated with
Qapre, post-PTA results (both post-PTA stenosis and stenosis
reduction) were not correlated with the subsequent decrease in
Qa. These data suggest that Qa, and therefore resistance, is
more predictive of the longevity of the effects of PTA than are
angiographic variables.
Also, the correlation between Qa and the decrease in Qa
deserves comment. It is likely that a greater Qa is an indica-
tion of greater dilation of the stenosis, probably corresponding
to more tissue injury. This may favor more rapid stenosis
recurrence. Indeed, there is some indication that less traumatic
dilation, for instance with a cutting balloon, results in less
activation of growth factors (reviewed in Reference 23).
The combined results of this study and the study by Schwab
et al. (18) warrant the initiation of a new discussion on the
optimal timing of PTA. It is tempting to hypothesize that
post-PTA patency in AVG is related to Qapre and/or the func-
tional result of the PTA. If this is the case, then PTA should be
performed as soon as a decrease in Qa is observed, as advo-
cated by some (18,26), rather than when a low Qa value is
reached, as proposed by others (7,27). In such cases, a “mild”
PTA procedure may result in a better long-term outcome than
a more vigorous one. The quality of patient care and the
cost-effectiveness of PTA may benefit importantly from prop-
erly designed studies addressing this hypothesis.
Possibly the best way to quantify the long-term effects of
PTA is to calculate secondary patency rates. However, this
study was not designed to address that issue. Many patients
were included in the surveillance and intervention program of
this study long after access implantation. Some of them had
undergone interventions before their inclusion in the study,
making it impossible to express the true secondary patency
rates for AVG followed by the surveillance and intervention
program, as in this study. However, survival estimations of our
secondary patency rates for AVG revealed a 6-mo patency rate
of 85% and a 1-yr patency rate of 79%. For AVF, survival
analysis demonstrated a 6-mo patency rate of 89% and a 1-yr
patency rate of 82%. With the aforementioned limitation in
mind, we can conclude that our secondary patency rate is
comparable to the literature data on secondary patency rates
(3,8).
The association between Qa and the risk of thrombosis is
less well documented for AVF than for AVG. AVF with Qa
levels of 300 to 500 ml/min can remain patent (3). Kidney
Disease Outcomes Quality Initiative recommends that AVF
should be monitored as AVG. The efficacy of PTA for AVF
was comparable to that for AVG. The long-term effects for
AVF seem substantially better than those for AVG. Primary
(post-PTA) patency rates for AVF ranged from 47 to 67% at 6
mo and from 16 to 62% after 12 mo (8). We observed a 6-mo,
intervention-free, primary patency rate of 50% and a median
survival time of 161 d for AVF. None of the investigated
variables was predictive of long-term results for AVF.
In conclusion, Qa increases after PTA but, in a substantial
percentage of cases, not to a level of 600 ml/min. Qa before
PTA and the increase in Qa were correlated with long-term
outcomes, whereas angiographic results were not. These data,
combined with the literature findings, suggest that there is
optimal timing for PTA.
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